Navigation Links
Tens of thousands of lives could potentially be saved by key heart failure therapies
Date:6/6/2011

A national study has found that nearly 68,000 deaths potentially could be prevented each year by optimally implementing key national guidelinerecommended therapies, including critical medications and cardiac devices, for all eligible heart failure patients.

Although heart failure is a major cause of death, morbidity and health care expenditures in the U.S., the routine clinical use of scientifically proven treatments that reduce mortality and improve quality of life has been slow and inconsistent.

"This is one of the first studies to quantify the potential survival benefits that could result if these guideline-recommended therapies were universally applied to all eligible heart failure patients in the United States," said the study's first author, Dr. Gregg C. Fonarow, UCLA's Elliot Corday Professor of Cardiovascular Medicine and Science and director of the AhmansonUCLA Cardiomyopathy Center at the David Geffen School of Medicine at UCLA.

Published in the June edition of the American Heart Journal, the findings help further the understanding of the possible health benefits of more consistent use of these heart failure therapies. The study also provides strong motivation for clinicians to improve implementation of these evidence-based treatments through performance-improvement initiatives and programs.

Heart failure occurs when the heart can no longer pump enough blood to the body's other organs. Often, patients with heart failure have reduced left-ventricle ejection fraction, which indicates a lowered volume of blood being pumped out of this heart chamber with each beat of the heart.

The study examined six evidence-based therapies for heart failure patients with reduced left-ventricle ejection fraction. The six therapies are highly recommended in the national guidelines of the American College of Cardiology and the American Heart Association for heart failure patients.

In conducting the study, investigators used a number of published sources, including clinical trials results, in-patient and out-patient patient registries for heart failure patients, and heart failure quality-of-care studies in cardiology and general clinical practice settings.

For each heart failure therapy, the study authors determined patient eligibility criteria, estimated the frequency of use, identified fatality rates and calculated mortality riskreduction statistics due to treatment.

They found that out of 2,644,800 heart failure patients with reduced left-ventricular ejection fraction in the U.S., many were eligible for the evidence-based therapies but did not receive them. The number of potential deaths that could be prevented each year with optimal implementation of all six therapies totaled 67,996, they said.

Potential lives saved by individual therapies alone are as follows:

Four heart failure medications

Aldosterone antagonists: 21,407 potential lives saved; beta blockers: 12,922; angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: 6,516; hydralazine/isosorbide dinitrate: 6,655

Cardiac resynchronization therapy

Potential lives saved with this device, which helps coordinate heart contractions: 8,317

Implantable cardioverter-defibrillator

Potential lives saved with this device, which delivers electrical shocks if potentially fatal heart rhythm abnormalities occur: 12,179

According to the researchers, the greatest potential gains were seen with those therapies for which the treatment gaps (number of patients who did not receive the therapy for which they were eligible) and the magnitude of benefits were the largest. Improved use of aldosterone antagonist therapy, followed by beta blocker and implantable cardioverter-defibrillator therapies, would provide the greatest benefit in possible lives saved, they said.

Mortality riskreduction due to treatment ranged from 17 percent with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers to 43 percent with hydralazine/isosorbide.

The number of heart failure patients who were eligible but not currently being treated ranged from 139,749 for hydrlazine/isorbide dinitrate to 852,512 for implantable cardioverter-defibrillators.

"With tens of thousands of lives potentially saved with optimal application of these therapies, the findings have significant clinical and public health implications," Fonarow said. "Determining the impact of each evidence-based therapy is helpful in prioritizing performance-improvement initiative efforts and planning future strategies to improve adherence."

Fonarow noted that the research estimated only reduction in deaths by optimal application of these therapies. Further study may evaluate hospitalization reductions, improvements in symptoms, functional status and other important clinical outcomes related to broader application of these therapies.


'/>"/>

Contact: Rachel Champeau
rchampeau@mednet.ucla.edu
310-794-2270
University of California - Los Angeles Health Sciences
Source:Eurekalert

Related medicine news :

1. Your Vote Can Make a Difference in the Lives of Thousands of Tennesseans
2. EarPeace Protects Hearing for Thousands at South by Southwest
3. Sokolove Law Helps Thousands of Consumers Fight Unfair Disability Insurance Denial
4. Thousands More ShelterBoxes to be Sent to Haiti
5. CA Dental Hygienists' Association to Provide Care to Thousands of Uninsured at Southland's Largest Free Public Health Clinic
6. Quick new screening exam could save thousands of people from bowel cancer
7. Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay
8. Thousands Drop The Weight For Good with HCG Diet Drops
9. Hearthside Home Care Urges Advocates to Object to the Institutional Bias of the NC Budget that will Deny Thousands Home Care
10. Anti-vomiting drug could prevent thousands of hospitalizations, save millions of dollars
11. Genomic markers may head off thousands of thyroid surgeries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Virginia Beach resident Sean Kelly ... turned towards the water to find peace and set out to accomplish a personal ... and turned to the internet. He came across the story of another special operations ...
(Date:6/23/2016)... ... 2016 , ... The annual Blue Ribbon Highlights Session took ... and Movement Disorders. This special session provides a critical review of the best ... of both clinical and basic research presented by delegates. , Of the ...
(Date:6/23/2016)... ... 2016 , ... The U.S. Supreme Court decision on immigration has significant consequences ... Senior Citizens League (TSCL) . “President Obama’s executive actions on immigration would have ... worked in this country illegally, even though the newly - issued green cards are ...
(Date:6/23/2016)... ... 23, 2016 , ... For the second time this year, ... Medical Education program, this time in pediatrics. The news from the Accreditation Council ... training that will begin in July 2017. ACGME had previously accredited Memorial’s Physical ...
(Date:6/23/2016)... Research Triangle Park, NC (PRWEB) , ... June 23, 2016 , ... ... Alzheimer’s disease, is announcing that the U.S. Food and Drug Administration (FDA) has granted ... T3D-959 in a limited number of subjects who completed the main Phase 2a study ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... June 23, 2016  The National Pharmaceutical Council ... the health policy research organization as its newest ... MD, senior vice president and chief scientific officer, ... on the NPC Board of Directors. ... Mallinckrodt has joined us in support of our ...
Breaking Medicine Technology: